Alpha Tau Treats First Pancreatic Cancer Patient in Italy, Expands Delivery Options for Alpha DaRT® Therapy
DRTS has more than doubled off its 52-week low of $2.57.
Summary
Alpha Tau Medical announced the successful treatment of the first pancreatic cancer patient in Italy with its Alpha DaRT® therapy, introducing a new dual delivery method that expands treatment accessibility.
Key Events · Product Development and Regulatory · DRTS
-
First Patient Treated in Italy
Alpha Tau successfully treated the first pancreatic cancer patient in Italy with its Alpha DaRT® therapy at the University of Verona's Pancreas Institute, as part of a new feasibility and safety study (CTP-PANC-03).
-
New Dual Delivery Method Introduced
The study is the first Alpha DaRT pancreatic cancer protocol worldwide to permit both endoscopic ultrasound (EUS)-guided and percutaneous delivery of Alpha DaRT sources, significantly expanding access alternatives for physicians.
-
Global Clinical Expansion
This treatment follows the first European patient treated in France in April 2026 and joins the ongoing IMPACT multicenter trial in the United States, reflecting the rapid global expansion of Alpha Tau's pancreatic cancer program.
Analysis · DRTS · Industrial Applications And Services
This filing marks a significant clinical milestone for Alpha Tau Medical, announcing the successful treatment of the first pancreatic cancer patient in Italy using its Alpha DaRT® therapy. Crucially, this study introduces a new dual delivery method, allowing for both endoscopic ultrasound (EUS)-guided and percutaneous placement of the Alpha DaRT sources. This expansion of delivery options is vital as it broadens the accessibility of the treatment to a wider range of patients and medical specialists, potentially accelerating adoption and market penetration. Pancreatic cancer remains one of the most lethal malignancies globally, with a particularly grim outlook in Italy, underscoring the high unmet medical need this therapy aims to address. This development reinforces the company's global clinical expansion strategy for its pancreatic cancer program, following recent positive data and ongoing trials in France and the United States.
At the time of this filing, DRTS was trading at $7.54 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $668M. The 52-week trading range was $2.57 to $9.07. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.